Amgen and AstraZeneca Trial Shows Significant Survival Benefit in Lung Cancer
What happened
Charles Rudin, director of Memorial Sloan Kettering Cancer Center, presented Phase III results from the DeLLphi-305 study. The trial compared Amgen’s DLL3-targeting BiTE therapy IMDELLTRA combined with AstraZeneca’s IMFINZI against IMFINZI alone. For patients with extensive-stage small-cell lung cancer, the combination therapy showed a 58% reduction in the risk of death compared to IMFINZI alone.
From themarketsdaily.com
Why it matters
The results were characterized as “practice-changing data”. This positive outcome validates the efficacy of IMDELLTRA and IMFINZI in combination treatment, impacting their market potential.
From themarketsdaily.com
Who's involved
- Memorial Sloan Kettering Cancer CenterHosted the presentation of the clinical trial results.
- AmgenDeveloped the DLL3-targeting BiTE therapy IMDELLTRA used in the trial.
- AstraZenecaProvided IMFINZI, which was used as the comparator and in combination therapy.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AmgenSpeculative
Amgen might see increased revenue potential for IMDELLTRA due to positive Phase III data.
- AstraZenecaSpeculative
AstraZeneca might see increased sales demand for IMFINZI when used in combination therapy.
Keep exploring
The entities involved
-
Memorial Sloan Kettering Cancer Center
cancer treatment and research institution in New York City, United States
-
Amgen
American multinational biopharmaceutical company